Oxygenta Pharmaceutical
Healthcare
524636 BSE
₹47.00
Close ·
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹47.00 −19.84 −29.7% 1Y
Start ₹66.84
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- −33.60%
- Debt to Equity
- Not meaningful: shareholders’ equity is negative
- EPS (TTM)
- −₹3.67
- Book Value
- −₹11.54
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- Not meaningful: book value is negative
- ROE
- Not meaningful: shareholders’ equity is negative
- Dividend Yield
- 0.00%
- EBITDA
- −₹15.10 Cr
- 52W High
- ₹71.59
- 52W Low
- ₹43.00
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
33 Poor
Data confidence 84/100
Category scores
- Quality
- 13
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 26
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 67
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 14
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 33
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is expected to give good quarter
- Company's median sales growth is 22.1% of last 10 years
Weaknesses
1- Company has low interest coverage ratio.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 8 | 1 |
| Oscillators | Bullish | 0 | 8 | 1 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Bearish
0
Neutral
8
Bullish
1
Overall
Strong Bearish
Bearish
10
Neutral
8
Bullish
1
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 42.61
- Neutral
- MACD (12,26,9)
- −0.92
- Bullish
- SMA (50)
- 50.92
- Bearish
- SMA (200)
- 52.54
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +25.14% |
|---|---|
| 5Y | +16.79% |
| 3Y | +53.90% |
| 1Y | +3.67% |
| TTM | +20.59% |
Net profit
| 10Y | Loss widened by ₹12 Cr |
|---|---|
| 5Y | Turned to loss |
| 3Y | Loss widened by ₹6 Cr |
| 1Y | Loss widened by ₹8 Cr |
| TTM | Loss narrowed by ₹1.47 Cr |
Operating cash flow
| 10Y | Turned negative |
|---|---|
| 5Y | Outflow widened by ₹26 Cr |
| 3Y | Outflow widened by ₹26 Cr |
| 1Y | Turned negative |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +20.06 pp |
|---|---|
| 5Y | −20.96 pp |
| 3Y | +9.31 pp |
| 1Y | −4.10 pp |
| TTM | +7.53 pp |
Revenue by year
| Mar 2017 | ₹8.00 Cr |
|---|---|
| Mar 2018 | ₹13.00 Cr |
| Mar 2019 | ₹21.00 Cr |
| Mar 2020 | ₹14.00 Cr |
| Mar 2021 | ₹52.00 Cr |
| Mar 2022 | ₹61.00 Cr |
| Mar 2023 | ₹31.00 Cr |
| Mar 2024 | ₹40.00 Cr |
| Mar 2025 | ₹109 Cr |
| Mar 2026 | ₹113 Cr |
Net profit by year
| Mar 2017 | −₹6.00 Cr |
|---|---|
| Mar 2018 | −₹5.00 Cr |
| Mar 2019 | −₹3.00 Cr |
| Mar 2020 | −₹6.00 Cr |
| Mar 2021 | ₹3.00 Cr |
| Mar 2022 | −₹1.00 Cr |
| Mar 2023 | −₹12.00 Cr |
| Mar 2024 | −₹3.00 Cr |
| Mar 2025 | −₹10.00 Cr |
| Mar 2026 | −₹18.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.86 | 13.08 | 9.15 | 10.55 | 12.62 | 14.01 | 33.21 | 49.47 | 15.13 | 14.3 | 33.93 | 49.61 | 37 |
| Expenses | 10.5 | 15.06 | 11.63 | 12.17 | 14.4 | 16.18 | 37.57 | 51.15 | 21.96 | 18.87 | 38.01 | 49.49 | 36.45 |
| Operating Profit | −3.64 | −1.98 | −2.48 | −1.62 | −1.78 | −2.17 | −4.36 | −1.68 | −6.83 | −4.57 | −4.08 | 0.12 | 0.55 |
| OPM % | −53.06% | −15.14% | −27.1% | −15.36% | −14.1% | −15.49% | −13.13% | −3.4% | −45.14% | −31.96% | −12.02% | 0.24% | 1.49% |
| Other Income | −0.13 | −0.03 | −0.02 | 0.26 | 0.02 | 0.75 | 0.49 | −0.22 | 0.16 | −0.06 | 0 | 0.17 | 0.02 |
| Interest | 0.29 | 0.34 | 0.36 | 0.59 | 0.41 | 0.69 | 0.39 | 2.13 | 0.63 | 0.95 | 1.39 | 1.81 | 2.46 |
| Depreciation | 0.5 | 0.83 | 0.69 | 0.64 | 0.65 | 0.66 | 0.71 | −0.23 | 0.85 | 0.86 | 0.86 | −0.24 | 0.62 |
| PBT | −4.56 | −3.18 | −3.55 | −2.59 | −2.82 | −2.77 | −4.97 | −3.8 | −8.15 | −6.44 | −6.33 | −1.28 | −2.51 |
| Tax % | 0% | −0.63% | 6.48% | −409.27% | −51.42% | 2.89% | −20.72% | −43.42% | −25.03% | −23.45% | −23.38% | 32.81% | −15.94% |
| Net Profit | −4.56 | −3.16 | −3.78 | 8.02 | −1.36 | −2.85 | −3.93 | −2.15 | −6.11 | −4.93 | −4.84 | −1.7 | −2.1 |
| EPS (₹) | −1.36 | −0.94 | −1.13 | 2.4 | −0.38 | −0.8 | −1.06 | −0.58 | −1.65 | −1.33 | −1.31 | −0.46 | −0.57 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 | 135 |
| Expenses | 10 | 16 | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 128 | 143 |
| Operating Profit | −4 | −4 | −5 | −4 | −2 | −8 | 4 | 1 | −7 | −10 | −10 | −15 | −8 |
| OPM % | −67% | −34% | −59% | −31% | −10% | −57% | 7% | 2.4% | −23% | −24% | −9% | −14% | −6% |
| Other Income | 0 | 0 | 1 | 1 | 0 | 4 | 2 | 1 | −1 | 0 | 1 | 0 | 0 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 5 | 7 |
| Depreciation | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 2 | 2 |
| PBT | −7 | −6 | −6 | −4 | −3 | −6 | 3 | 0 | −11 | −14 | −14 | −22 | −17 |
| Tax % | −11% | 0% | 2% | 1% | −7% | −3% | 7% | 24% | 2% | −75% | −28% | −21% | — |
| Net Profit | −6 | −6 | −6 | −5 | −3 | −6 | 3 | −1 | −12 | −3 | −10 | −18 | −14 |
| EPS (₹) | −5.99 | −5.39 | −5.7 | −4.44 | −3.19 | −5.68 | 2.87 | −0.43 | −8.15 | −1.04 | −2.79 | −4.75 | −3.67 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | −26 | −32 | −38 | −42 | −45 | −51 | −48 | −49 | −60 | −54 | −63 | −80 |
| Borrowings | 15 | 17 | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 110 |
| Other Liabilities | 19 | 24 | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 53 |
| Total Liabilities | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
| Fixed Assets | 12 | 13 | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 37 | 48 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6 | 7 | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 46 | 72 |
| Total Assets | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −4 | 1 | 1 | 1 | −8 | −3 | −2 | −2 | −2 | −13 | 3 | −28 |
| Investing | 1 | −2 | −1 | 0 | −1 | 0 | −7 | −5 | −10 | −4 | −11 | −14 |
| Financing | 3 | 1 | 0 | −1 | 8 | 3 | 9 | 6 | 11 | 17 | 8 | 43 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | −7 | −1 | 0 | 1 | −8 | −3 | −8 | −7 | −11 | −17 | −8 | −41 |
| CFO/OP | 104 | −20 | −13 | −33 | 396 | 35 | −37 | −106 | 23 | 135 | −29 | 182 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 38 | 44 | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 | 32 |
| Inventory Days | 84 | 41 | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 | 105 |
| Days Payable | 1,800 | 667 | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 | 174 |
| Cash Conversion Cycle | −1,678 | −582 | −439 | −325 | −73 | −79 | −5 | 16 | −64 | −32 | −18 | −37 |
| Working Capital Days | −616 | −454 | −512 | −438 | −164 | −275 | −14 | 8 | −94 | −89 | −184 | −119 |
| ROCE % | — | — | — | — | — | — | — | −1% | −47% | −42% | −33% | −34% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Oxygenta Pharmaceutical insights
59 extracted metrics across FY11–FY27.
Documents
- General announcements 13 Oct 2026
- General announcements 1 Oct 2026
Frequently Asked Questions about Oxygenta Pharmaceutical
What does Oxygenta Pharmaceutical Ltd do?
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
Where is Oxygenta Pharmaceutical Ltd (OXYGENTAPH) listed?
Oxygenta Pharmaceutical Ltd trades under code 524636 on the BSE.
Which sector does Oxygenta Pharmaceutical Ltd belong to?
Oxygenta Pharmaceutical Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Oxygenta Pharmaceutical Ltd?
Over the last 52 weeks Oxygenta Pharmaceutical Ltd has traded between ₹43 and ₹71.59 as of 4 Nov 2026.
Company Information
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
Website oxygentapharma.com
CEO Mr. Prasad Reddy Battinapatla
Employees 175
Listed 20 Oct 1997
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524636.md for Oxygenta Pharmaceutical Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.